Retatrutide FDA Approval Timeline: What Lilly Has Said and What Happens Next
As of the last public report, Lilly had not filed an FDA application for retatrutide. It has said it will in the first quarter of 2027. A filing starts a review that FDA describes as taking 6 to 10 months, so on Lilly’s plan an approval in 2026 is not possible.
Dates on this page are company plans and FDA process ranges, not predictions. The filing date can move, and review time depends on what the review finds. This page covers the US only; other regulators run their own reviews.
What Lilly has said about filing
In July 2026, BioPharma Dive reported that Eli Lilly will file an approval application for retatrutide in the first quarter of 2027. The same report said the company told CNBC it needed more time to gather manufacturing and quality-control data for the agency.
The reason given was manufacturing data, not the trial results. That matters because FDA approves a particular product made to a particular standard, not a molecule in the abstract, so the manufacturing file is part of the application.
What a filing starts
A filing is the start of a review, not the end of one. FDA describes the review team as having 6 to 10 months to decide whether to approve a drug. The agency may also convene one of its advisory committees to get independent expert advice, and those committees include a patient representative.
The table sets the known steps beside their sources. Only the filing has a stated target date, and that date is a company plan.
| Step | What happens | Timing | Source |
|---|---|---|---|
| Filing | Lilly submits its approval application | Planned for the first quarter of 2027 | BioPharma Dive, July 2026 |
| FDA review | The review team decides whether to approve | 6 to 10 months | FDA drug review overview |
| Advisory committee | Independent experts advise FDA, if one is convened | No fixed date and not always used | FDA drug review overview |
What those numbers imply, and what they do not
Put the two facts together. If Lilly files in the first quarter of 2027 and review takes the 6 to 10 months FDA describes, a decision would arrive in the second half of 2027 at the earliest and could run into 2028.
That is arithmetic on stated ranges, not a forecast. It assumes the filing is not delayed, is accepted without complications and does not prompt requests for more information, and any of those would push the date back. It also assumes approval, which is a separate question from timing.
What can move the date
- The filing slips past the first quarter of 2027
- FDA asks for additional information or data during review
- An advisory committee meeting is scheduled
What a planned filing does not change
Until FDA approves it, retatrutide has no prescribing information, no approved dose and no authorized prescription product. Strong trial results and a filing plan describe how far the sponsor has got. They are not a regulatory decision.
On Lilly’s stated plan, an approval in 2026 is not possible, because approval follows a filing that has not happened yet. Anyone offering retatrutide as an approved medicine today is describing something that does not exist.
What to watch for next
Check FDA and Lilly directly for anything after the July 2026 report this page relies on.
- Lilly announcing that the application has been submitted
- FDA accepting the application for review
- Status changes on the Phase 3 study records at ClinicalTrials.gov
- Peer-reviewed publication of the Phase 3 results, which are so far company-reported
- Notice of an advisory committee meeting
Common Questions
When will retatrutide be approved?
No approval date exists. Lilly plans to file in the first quarter of 2027 (BioPharma Dive, July 2026). FDA describes 6 to 10 months for review, so on those figures a decision would come in the second half of 2027 at the earliest.
Has Lilly filed for FDA approval of retatrutide?
Not as of the July 2026 report this page relies on. Lilly said it will file in the first quarter of 2027. Check Lilly and FDA for any update after that report.
Could retatrutide be approved in 2026?
Not on Lilly’s stated plan. An approval decision follows a filing, and the filing is planned for 2027.
Does a filing mean approval?
No. A filing starts FDA’s review. The agency then decides whether to approve, and it may convene an advisory committee first.
Why is Lilly waiting to file if the trial results are positive?
The reason reported was manufacturing and quality-control data that the company needed more time to gather for the agency, not the trial results.
References
- BioPharma Dive. Report on Eli Lilly's planned FDA application for retatrutide, including the first-quarter 2027 filing timeline. July 23, 2026.
- U.S. Food and Drug Administration. Step 4: FDA Drug Review. The Drug Development Process.
- ClinicalTrials.gov. TRIUMPH-5: Retatrutide Compared With Tirzepatide in Adults With Obesity. NCT06662383.
References were checked against the journal, PubMed or ClinicalTrials.gov record. Company-reported topline results are labeled as such.